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Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disease
with an incidence of 1 in 400 to 1000. The disease is genetically heterogeneous, with two genes identified: PKD1
(16p13.3) and PKD2 (4q21). Molecular diagnosis of the disease in at-risk individuals is complicated due to the
structural complexity of PKD1 gene and the high diversity of the mutations. This study is the first systematic
ADPKD mutation analysis of both PKD1 and PKD2 genes in Chinese patients using denaturing high-performance
liquid chromatography (DHPLC).
Methods: Both PKD1 and PKD2 genes were mutation screened in each proband from 65 families using DHPLC
followed by DNA sequencing. Novel variations found in the probands were checked in their family members
available and 100 unrelated normal controls. Then the pathogenic potential of the variations of unknown
significance was examined by evolutionary comparison, effects of amino acid substitutions on protein structure,
and effects of splice site alterations using online mutation prediction resources.
Results: A total of 92 variations were identified, including 27 reported previously. Definitely pathogenic mutations
(ten frameshift, ten nonsense, two splicing defects and one duplication) were identified in 28 families, and
probably pathogenic mutations were found in an additional six families, giving a total detection level of 52.3%
(34/65). About 69% (20/29) of the mutations are first reported with a recurrent mutation rate of 31%.
Conclusions: Mutation study of PKD1 and PKD2 genes in Chinese Hans with ADPKD may contribute to a better
understanding of the genetic diversity between different ethnic groups and enrich the mutation database. Besides,
evaluating the pathogenic potential of novel variations should also facilitate the clinical diagnosis and genetic
counseling of the disease.
Background
Autosomal dominant polycystic kidney disease (ADPKD)
is a severe inherited disorder accounting for up to 10% of
end-stage renal diseases [1]. The disease is characterized
by numerous gradually enlarging fluid-filled epithelial
cysts in bilateral kidneys. Two mapped genes, PKD1
(MIM 601313) and PKD2 (MIM 173910), are known to
cause the disease [2,3]. The former, mutated in 85% of all
cases, encodes polycystin-1 (PC1), which is a receptor
protein for cell-cell/matrix interactions in the regulation
of cell proliferation and apoptosis; the latter, mutated in
15% of the cases, encodes polycystin-2 (PC2), which
functions as a transient receptor potential ion channel
and regulates intracellular Ca
2+ concentration. PC1 inter-
acts with PC2 to form a functional complex that acts as a
flow-dependent mechanosensor for regulating the differ-
entiated state of tubular epithelial cells [4-7].
Early diagnosis of ADPKD is established primarily by
ultrasound imaging with age-related cyst number criteria
[8], however, for younger at-risk individuals and those
with PKD2 mutations, ultrasonography may be insuffi-
cient for providing a definite diagnosis [9,10]. In such
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n o s i s ,b u ti tr e q u i r e st h ep a r t i c i p a t i o no fa tl e a s tt w o
affected relatives. In recent years, mutation screening, a
direct and efficient approach, has been proven applicable
to all cases suspected of ADPKD. According to a recent
study, the mutation detection rate is approximately 86%
using a combination of SURVEYOR Nuclease-Wave HS
analysis and direct sequencing [11]. However, mutation
screening of PKD genes for clinical diagnostic purposes
has been proven difficult because of the structural com-
plexity of PKD genes and the high diversity of their
mutations.
The PKD1 gene encodes an approximately 14 Kb tran-
script with 46 exons extending to 50 kb of the genomic
DNA [12] and the 5’ part of this gene covering exons 1-33
is duplicated three or more times proximally on chromo-
some 16 [13]. Therefore, locus-specific amplification of
PKD1 is required to acquire a single copy of the gene’s
duplicated region. PKD2, which encodes a 3 kb open read-
ing frame with 15 exons, extends to a 70 kb genomic area
[14]. Furthermore, no hot mutation in both genes has
been reported, and distinguishing the pathogenic muta-
tions from non-pathogenic variations remains a major dif-
ficulty in direct gene diagnosis of the disease.
In the present study, a group of novel mutations discov-
ered from the direct mutation screening of both PKD1
and PKD2 in 65 Chinese families with ADPKD were
described. A total of 100 unrelated normal controls were
also recruited to differentiate between possible mutations
and polymorphic changes. All mutation data detected
would be helpful in direct gene diagnosis, as well as in
genetic counseling in clinical practice.
Methods
The patients and the normal controls
A total of 121 individuals from 65 unrelated families were
recruited from West China Hospital, Sichuan University.
Among them, 86 individuals were diagnosed with ADPKD
according to the ultrasound criteria recommended by
Ravine et al. The general clinical data of the patient cohort
are summarized in Table 1. In addition, 100 unrelated
healthy volunteers 35 to 56 years old were also recruited
as controls after exclusion of any renal cysts by ultrasound
examination. Peripheral blood samples were collected
from all participants, with prior informed consent. This
study was approved by the Institutional Ethical Review
Boards, Sichuan University.
PCR amplification
For each proband, the genomic DNA was extracted
from the peripheral blood sample using a standard phe-
nol-chloroform procedure and prepared in duplicate.
The duplicated region of PKD1 encoding exons 1-33
was amplified as five specific long fragments, and
electrophoresed on 1% agarose gel to detect the possible
large range of sequence rearrangement [15-17]. Then,
the five long-range PCR products were diluted 1:10
4 to
avoid genomic DNA carryover, and served as templates
for 50 nested PCR reactions. Meanwhile, exons from the
unique region of PKD1 gene and the entire PKD2 gene
were amplified from the genomic DNA by 31 additional
PCR reactions. A total of 81 PCR products, ranging
from 150 to 450 bp, were separated on 2.0% agarose gel
to check the amplification efficiency, then were prepared
for DHPLC analysis.
Mutation screening by DHPLC
DNA fragments were analyzed using an automated WAVE
Nucleic Acid Fragment Analysis System (Transgenomic,
Omaha, Nebraska). Wavemaker 4.2 software (Transge-
nomic, Omaha, Nebraska) was used to determine the opti-
mal melting temperature for the tested fragments.
Heteroduplexes of amplicons were generated prior to
DHPLC by denaturing the PCR products at 94°C for 5
m i na n dc o o l i n gt h e ma tr o o mt e m p e r a t u r ef o r4 5m i n .
Then, about 5-8 μL of each product was injected into a
high-throughput DNASep column and eluted with a linear
acetonitrile gradient of 2% per minute at a flow rate of 0.9
mL min
-1. All chromatograms were grouped based on the
differences in profiles between the normal controls and
patients.
DNA sequencing
All fragments with aberrant elution profiles were
sequenced to confirm the possible changes using the same
forward and reverse PCR primers used for the PCR ampli-
fications. The change was checked with the duplicate sam-
ple after it was found. A necessary cloning and sequencing
of the fragment was performed if more than one sequence
changes were observed in a DNA fragment. The NCBI
RefSeq sequences were used for PKD1 [GeneBank:
Table 1 General clinical data of the studied patients
General description Rate (N = 65)
a
%Female 49.3%
Average age at the time of test (years) 47.2 (range, 28-79)
%ESRD
b 29.8%
Average GFR (mL/min)
c 41.4 (range, 3.4-105.1)
Average Serum creatinine concentration
(μmol/L)
310.8 (range, 52.0-
1022.8)
Average BUN (mmol/L)
c 12.3 (range, 3.4-41.8)
%With family history
d 72.6%
a Data summarized from 65 probands.
b ESRD defined as transplant, dialysis, or Modification of Diet in Renal Disease
(MDRD) GER < 10 mL/min.
c MDRD GFR = 186 × (Scr/88.4)
-1.154 × Age
-0.203 × (0.742 if female). Scr, Serum
Creatinine in μmol/L; BUN, blood urea nitrogen in mmol/L.
d Data obtained from the probands and their living family members.
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Page 2 of 7NM_001009944.2] and PKD2 [GeneBank: NM_000297.3]
in this study. The standard nomenclature recommended
by HGVS was used to number nucleotides and name
mutations or variations [18,19].
Evaluation of the pathogenicity of sequence variations
Frame-shifting deletions or insertions, nonsense, typical
splicing and in-frame changes of five or more amino acids
were defined as pathogenic mutations in this study [20].
Pathogenic potential of missense, intronic changes and
synonymous were evaluated using a method recom-
mended by Tan et al.
Firstly, gene variations were classified by analyzing
recurrence as reported in the literature, ADPKD mutation
database (PKDB) [21] and Single Nucleotide Polymorph-
ism database (dbSNP). Secondly, novel variations and pre-
vious unclassified variations were checked in family
members available and 100 unrelated normal controls.
Variations found in unaffected family members or unre-
lated normal controls were classified as polymorphisms.
Then, the functional significance of the remaining unclas-
sified variations was evaluated computationally using web-
based software programs. SIFT and PolyPhen-2 were used
to predict possible impact of substitutions on protein
function and/or structure [22-26]. The Align-GVGD pro-
gram was used to determine the Grantham Matrix Score
(GMS) for evaluating evolutionary conservation (Gran-
tham Variation[GV]) and chemical differences of resulting
amino acid substitutions (the Grantham Distance[GD])
[27-29]. Potential splice-site effects were predicted using
NNSplice and NetGene2 with default settings for mis-
sense, synonymous, and intronic changes [30-34].
All variations analyzed by these web-based software pro-
grams were finally sorted into four categories: 1) probable
pathogenic; 2) indeterminate; 3) probable polymorphism;
and 4) polymorphism. Only gene variations that were
unanimously predicted to be deleterious by SIFT, Poly-
Phen-2 and Align-GVGD or to affect splicing by NNSplice
and NetGene2 were considered to be “probably patho-
genic”, if no other definite mutation was found in the
same patient. If a definite mutation coexisted with a dele-
terious missense change or a likely atypical splicing varia-
tion in the same patient, the missense change and the
atypical splicing variation were considered to be “indeter-
minate”. Similarly, only variations that were scored as
begin or predicted to have no effect on splicing by all cor-
responding applications were considered to be “poly-
morphisms”. Otherwise, they were classified as “probable
polymorphisms”.
Results
In total, 92 different gene variations were detected. Among
them, 23 pathogenic mutations and 6 probably pathogenic
mutations, with 26 located in PKD1 and 3 in PKD2, were
found in 34 families (Table 2), giving a mutation detection
rate of 52.3% (34/65). Novel mutations were found in 69%
(20/29) of the mutations with a recurrent rate of 31% (9/
29). The most common mutation, NM_001009944.2:
c.5014_5015delAG, was found in three families. Two non-
sense mutations (NP_001009944.2: p.Tyr2796* and
NP_000288.1: p.Arg325*), one deletion (NP_001009944.2:
p.Asn2925Tyrfs*10) were found twice.
Definite mutations were found in 28 of the families
including 10 frameshift, 10 nonsense, two typical splicing
and one duplication of five amino acids. These disease-
causing mutations are reported in Table 3. Totally 28
missense changes were detected in the patients, of which
9 were reported as polymorphisms previously. Addition-
ally, NP_001009944.2: p.Ser372Asn and p.Arg2654Gly
that coexisted with a definite mutation NP_001009944.2:
p.Arg2430* in patient 09032 were found in unaffected
family members; NP_001009944.2: p.Leu1290Val that
coexisted with NP_001009944.2: p.Arg462fs in patient
08006, NP_001009944.2: p.Arg3169Gln that coexisted
with NP_001009944.2: p.Trp3785* in patient 08020, and
NP_001009944.2: p.Ala1792Thr in patient 09026 were
found in unrelated normal controls; these five missense
variations were classified as polymorphisms. The patho-
genic potential of the remaining 14 unclassified missense
changes were evaluated by SIFT, PolyPhen-2 and Align-
GVGD (see Additional file 1). Finally, additional six were
predicted to be deleterious by all three software applica-
tions, and classified as “probably pathogenic” (Table 4);
two were scored as benign unanimously and defined as
“polymorphisms"; others scored as deleterious by only
one or two of these applications were considered to be
“probable polymorphisms”.
Novel synonymous variations, intronic changes, and mis-
sense variations scored as “benign” or “unclassified” by
SIFT, PolyPhen-2 and Align-GVGD were evaluated for
splice-site effects (see Additional file 2). Three variations,
NM_001009944.2: c.7704-12C > T, NM_001009944.2:
c.7796T > G (p.Leu2599Arg), and NM_001009944.2:
Table 2 Characteristics of the detected mutations
Description PKD1 PKD2 Total
Pathogenic 21 3 23
Probably pathogenic 5 1 6
FS deletion/insertion/duplication 10 0 10
Nonsense 9 1 10
Splicing 1 1 2
IF deletion/insertion 1 0 1
Missense 5 1 6
Recurrent mutations 7 2 9 (31%)
Novel mutations 19 1 20 (69%)
Total mutations detected 26 (89.7%) 3 (10.3%) 29
FS, frame-shift; IF, in-frame.
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slight effect on splice-site by only one of the applications
and therefore were considered to be “probable polymorph-
isms”. Based on the analysis criteria indicated above, six
variations were predicted to be “probably pathogenic”,
eight were classified as “probable polymorphisms”, and 55
were classified as “polymorphisms”. These polymorphisms
and probable polymorphisms are shown in Additional
file 3.
Discussion
Mutation analysis of PKD1 and PKD2 in Chinese ADPKD
patients previously focused on the unique region of the
genes [35-37], only one systematic mutation analysis of
Table 3 Details of pathogenic mutations observed from PKD1 and PKD2
Patient ID Region cdna Change Amino Acid Change Type Previous description
PKD1
08006 IVS7 c.1606+1G > A p.Arg462fs Splice PD
09065 EX9A c.1779delA p.Glu593Aspfs*192 Frameshift Novel
09030 EX13 c.3058C > T p.Gln1020* Nonsense PD
09041 EX15B c.3824delG p.Gly1275Valfs*71 Frameshift Novel
09052 EX15E c.4746G > A p.Trp1582* Nonsense PD
08011 EX15F c.5014_5015delAG p.Arg1672Glyfs*98 Frameshift PD
08019 EX15F c.5014_5015delAG p.Arg1672Glyfs*98 Frameshift PD
09034 EX15F c.5014_5015delAG p.Arg1672Glyfs*98 Frameshift PD
09060 EX15H c.5595delG p.Leu1866Serfs*83 Frameshift Novel
09056 EX15H c.5722C > T p.Gln1908* Nonsense Novel
08013 EX15M c.6424C > T p.Gln2142* Nonsense Novel
09024 EX15N c.6650_6664dup15 p.Val2217_Leu2221dup Duplication Novel
09069 EX15N c.6730_6731delAG p.Ser2244Hisfs*17 Frameshift Novel
08008 EX15N c.6781delG p.Glu2261Argfs*53 Frameshift Novel
09032 EX18 c.7288C > T p.Arg2430* Nonsense PD
09031 EX23A c.8388T > A p.Tyr2796* Nonsense Novel
09042 EX23A c.8388T > A p.Tyr2796* Nonsense Novel
08023 EX23B c.8614DelA p.Ile2872Serfs*3 Frameshift Novel
08002 EX23B c.8772_8776delCAACT p.Asn2925Tyrfs*10 Frameshift Novel
09066 EX23B c.8772_8776delCAACT p.Asn2925Tyrfs*10 Frameshift Novel
09037 EX29 c.9840_9843dupGGCC p.Thr3282Glyfs*109 Frameshift Novel
09035 EX35 c.10527_10528delGA p.Glu3509Aspfs*117 Frameshift Novel
08020 EX40 c.11354G > A p.Trp3785* Nonsense Novel
09063 EX44 c.12013C > T p.Gln4005* Nonsense PD
09058 EX44 c.12061C > T p.Arg4021* Nonsense PD
PKD2
09047 EX4 c.973C > T p.Arg325* Nonsense PD
09070 EX4 c.973C > T p.Arg325* Nonsense PD
09036 IVS4 c.1094+1G > C p.Ala365fs Splice PD
PD, previously described in other studies, details in the Human Gene Mutation Database (HGMD) and/or the Autosomal Dominant Polycystic Kidney Disease:
Mutation Database (PKDB).
Table 4 Details of the probably pathogenic mutations
Patient ID Region cdna change Amino Acid Change Type Previous description
PKD1
08012 EX15E c.4810G > A p.Val1604Met Substitution Novel
09049 EX26 c.9335G > T p.Cys3112Phe Substitution Novel
08009 EX26 c.9388C > T p.Arg3130Trp Substitution Novel
09028 EX29 c.9884A > G p.Asn3295Ser Substitution Novel
09040 EX40 c.11285C > T p.Pro3762Leu Substitution Novel
PKD2
09039 EX4 c.1034A > G p.Tyr345Cys Substitution Novel
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tion polymorphism (SSCP) has been reported, which con-
tained only 24 families [38]. Therefore, it is essential to
understand how mutations are distributed in all regions of
the genes in Chinese patients and the genetic diversity
between different ethnic groups. The present study has
analyzed 65 ADPKD families using DHPLC and DNA
sequencing, giving a mutation detection rate of 52.3%.
Among the 29 mutations, 69% are reported for the first
time, and recurrent mutations account for about 31%. No
hot mutation was found in this study.
Gene mutations detected in the study include frame-
shift, nonsense, missense, and splice-site changes, and
the proportion of each type of mutation is in agreement
with that reported by Rossetti et al. (P > 0.05, Chi-square
Test). In total of 62 variations detected in PKD1 gene of
the patients, 21 variations were located in exon 15, and
accounted for 33.9% (21/62) which is higher than that
recorded in PKDB (181/873) (P < 0.05, Chi-square Test).
No definitely pathogenic mutation that coexisted with
another mutation in a same patient was found in our
study of Chinese patients, only some missense, synon-
ymous, or intronic changes were found to coexist with a
definite pathogenic mutation, but were scored as benign
according to the analysis criteria. A duplication of five
amino acids (NP_001009944.2: p.Val2217_Leu2221dup)
found in patient 09024 was an exonic rearrangement that
may affect the structure of the protein, therefore, was
classified as a pathogenic mutation as recommended by
Rossetti et al.
A number of sequence changes in the 5’ replicated
region of PKD1 were also present in their homologous
locis, such as the mutations NM_001009944.2: c.7288C
> T (p.Arg2430*), c.8614DelA (p.Ile2872Serfs*3), and
four polymorphisms, NM_001009944.2: c.1849
+14_1849+26delTGGTGGGTGGTGG, c.8087T > G (p.
Leu2696Arg), c.8681_8689delCCAACTCCG (p.
Ala2894_Ser2896del) and c.9506G > A (p.Arg3169Gln).
Nucleotide sequences of PKD1 exhibiting these
changes were identical to at least one of their homolo-
gous copies on chromosome 16. A similar phenom-
enon was also observed in other ethnic groups [39,40],
especially in a population of 41 unrelated Thai and six
unrelated Korean families with ADPKD by Phakdee-
kitcharoen et al. A possible reason for the phenom-
enon is that gene conversion has happened between
PKD1 and its homologous loci [41,42]. Nevertheless,
this kind of variations should be interpreted carefully
when utilized in clinical diagnosis.
Because of the high prevalence of polymorphisms and
private mutations, particularly in PKD1, it is difficult to
determine whether a specific genetic change is a muta-
tion or a polymorphism. In the present study, all novel
variations and previous unclassified variations were first
checked in family members and unrelated normal con-
trols. Then the pathogenic potential of the remaining
variations were analyzed by web-based software applica-
tions. SIFT, PolyPhen-2, NNSplice, and NetGene2 were
used with default setting. The GMS was used to score
the GD and GV of each substitution, and this method
has been currently automated in the program Align-
GVGD. All analyses have finally identified additional six
probably pathogenic mutations, increasing the overall
detection rate to 52.3%, and this result demonstrates the
utility of bioinformatics evaluation of gene variations in
PKD genes.
DHPLC is a well-known method that could be used
for the detection of heterozygous variants. However,
DNA fragments with variants located in the GC-rich
region or the 5’ and 3’ ends nearby tend not to generate
recognizable elution peaks, which could lead to false
negative results [43]. Therefore, direct sequencing both
PKD1 and PKD2 genes of patients, especially the muta-
tion-negative cases, could be one of the most efficient
methods for mutation detection. Large deletions and
duplications were reported to account for 1%-3% of the
mutations in PKD1 patients [44,45], however, if the
rearrangement extends beyond the limits of the large
amplicons, only the wild-type would be amplified by
PCR. For this kind of mutations, multiplex ligation-
dependent probe amplification may serve as a more reli-
able detection assay [46,47]. Considering the structural
complexity of the PKD1 gene and the diversity of muta-
tion types, a combination of multiple methods rather
than a single assay is highly recommended to meet the
patients’ demand for a complete molecular genetic diag-
nosis of ADPKD.
Conclusions
The present mutation analysis of PKD1 and PKD2 genes
in Chinese Hans with ADPKD may contribute to a bet-
ter understanding of the genetic diversity between dif-
ferent ethnic groups and enrich the mutation database.
Besides, evaluating the pathogenic potential of novel
variations should also facilitate the clinical diagnosis and
genetic counseling of the disease, particularly through
the direct gene approach.
Additional material
Additional file 1: Supplementary Table S1. Evaluation of the
Pathogenic Potential of Missense Variants. The pathogenic potential
of missense variants was evaluated by SIFT, PolyPhen-2 and Align-GVGD.
For Align-GVGD analysis, an multisequence alignment (MSA) was
generated using the software T-coffee http://tcoffee.crg.cat/apps/tcoffee/
play?name=regular of PKD1 orthologs from human (GI 205360954),
monkey (GI 297283254), mouse (GI 124487380), rat (GI 293351352), dog
(GI 54792752), chicken (GI 118097923), frog (Xenopus [Silurana] tropicalis
GI 301605771), fish (Fugu, ENSTRUP0000002017). For PKD2, human (GI
4505835), monkey (GI 109074954), mouse (GI 164519057), rat (GI
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Page 5 of 7300794239), dog (GI 74002219), chicken (GI 71896749), frog (GI
301618537), fish (Danio rerio GI50539686), cow (GI 114052611), fish
(Oryzias latipes GI 211904097), pig (Sus scrofa GI 311262841) were used.
Sequences were obtained from NCBI or Ensembl database. We entered
the two gene alignments using default settings. This method has been
currently automated in the program Align-GVGD.
Additional file 2: Supplementary Table S2. Atypical splicing
prediction. Atypical splicing prediction of novel synonymous variations,
intronic changes, and missense variations was performed using NNSplice
and NetGene2.
Additional file 3: Supplementary Table S3. Summary of PKD1 and
PKD2 Genetic Variations (Polymorphisms, Probable Polymorphisms).
A brief summary of polymorphisms and probable polymorphisms
detected from patients, unaffected family members and normal controls
in this study.
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